[China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110

Announced Date: 2025-10-17 (October 17, 2025)

Licensor (Seller): Hansoh Pharma (China)

Licensee (Buyer):  Roche

.

Asset Name: HS-20110

Asset Modality: Antibody-drug conjugate (ADC) 

Antibody Target: Humanized anti-CDH17 monoclonal antibody 

ADC Payload: Validated topoisomerase inhibitor (TOPOi) payload

Potential Indication: Solid tumors including colorectal cancer (CRC)

Current Stage: Global  Phase I trial underway in China and the United States

.

Scope of Authority:

Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to progress the clinical development and commercialization of HS-20110.

.

Payment Detail:

Hansoh Pharma will receive:

an upfront payment of US$80 million,

up to US$ 1.45 billion milestone payments,

royalties on potential future product sales.

.

Link:

HANSOH GRANTS ROCHE AN EXCLUSIVE LICENSE TO NOVEL CDH17-TARGETING ADC HS-20110-Press Releases-Hansoh Pharmaceutical Group Co., Ltd. (hspharm.com)

.

Note:

Chinese Name of Hansoh Pharma, 瀚森制药、豪森药业